World Health Organization Issues Concern Over Acute Lack of Weight-Loss Injections
Less than one in 10 individuals who could benefit from weight-loss injections such as Wegovy are able to get them, states the World Health Organization as it releases its first advice on the therapies.
Considering in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is advocating for more widespread and fairer availability to these injectable treatments.
Based on estimates, in excess of 2,000,000,000 are projected to be living with obesity by 2030 without intervention.
"Our new guidance affirms that excess weight is a long-term condition that can be managed with comprehensive and ongoing support," said the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and distribution challenges are major barriers to broad access to the treatments that can aid individuals in losing substantial body mass, notes the organization.
Weight-Loss Drug Shortage
Despite the current most optimistic scenario, the manufacturing of such drugs would only suffice for about 100 million people – under 10% of the global need, according to the health organization.
The guideline urges nations and manufacturers to widen availability, by strategies such as patent sharing.
Exclusive production rights on semaglutide – the main component of the drug Wegovy – is scheduled to end in a number of countries in 2026.
How Obesity Injections Work
GLP-1 drugs mimick a biological compound to delay gastric emptying, reduce hunger and increase the sense of being full so users reduce food intake.
Individuals typically see weight reduction in the initial weeks of beginning the once-weekly jabs.
Evidence suggests patients may regain a significant portion within a year of halting the medication, as their usual appetite resume.
Being overweight or obese elevates your likelihood for contracting diseases, including type 2 diabetes, cardiovascular issues, stroke, and certain cancers.
Excess weight affects people in all nations and was linked to 3.7 million fatalities worldwide in 2024, as per the WHO.
